Acetylcysteine for the Prevention of Liver Injury in Covid-19 Patients

Phase 3

Recruiting

• Conditions: Condition 1: COVID-19 pneumonia. Condition 2: Acute liver injury.; Pneumonia due to SARS-associated coronavirus; Acute and subacute hepatic failure; J12.81; K72.0

• Registration Number: IRCT20210726051995N1
• Lead Sponsor: Artesh University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 August 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

Diagnosed positive for Covid-19 based on PCR testing
Admitted in intensive care unit
Treated with remdesivir

Exclusion Criteria

Positive history of any underlying liver disease e.g. fatty liver, or acute or chronic hepaptitis
Plasma levels of liver transaminases over 100 IU/L on the first day of ICU admission
Simultaneous use of any hepatotoxic drugs

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The prevention of acute liver injury. Timepoint: Days 1, 2, 3, 4 and 5 of trial. Method of measurement: Laboratory measurement of serum levels of liver aminotransferases.

Secondary Outcome Measures

Name	Time	Method
Total bilirubin serum levels. Timepoint: Days 1, 2, 3, 4 and 5 of trial. Method of measurement: Laboratory measurement.;Prothrombin time. Timepoint: Days 1, 2, 3, 4 and 5 of trial. Method of measurement: Laboratory measurement.